ProfileGDS5678 / 1421336_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 14% 14% 14% 13% 13% 14% 14% 14% 13% 13% 14% 14% 14% 14% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.3729114
GSM967853U87-EV human glioblastoma xenograft - Control 22.3435414
GSM967854U87-EV human glioblastoma xenograft - Control 32.3485414
GSM967855U87-EV human glioblastoma xenograft - Control 42.2685213
GSM967856U87-EV human glioblastoma xenograft - Control 52.2864113
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4074614
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.3643514
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3206114
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3081513
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.3155813
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.3279114
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3142214
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3461314
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.3348714